Joyce Sutcliffe, Senior Vice President of Biology at Tetraphase, to give featured presentation at 7t
Joyce Sutcliffe, Senior Vice President of Biology at Tetraphase, will give a featured presentation on “TP-434: A Novel, Gram-Negative Antibiotic in Clinical Development” at the 7th Anti-Infectives Partnering and Deal-making Summit to be held in Boston, MA on October 7-8, 2010 by GTCbio.
[USPRwire, Sat Aug 14 2010] Joyce Sutcliffe, Senior Vice President of Biology at Tetraphase to give featured presentation at GTCbio’s 7th Anti-infectives Partnering and Deal-Making Summit taking place on October 7-8, 2010 in Boston, MA.
Joyce Sutcliffe will give a featured presentation on “TP-434: A Novel, Gram-Negative Antibiotic in Clinical Development” at the 7th Anti-Infectives Partnering and Deal-Making Summit to be held in Boston, MA on October 7-8, 2010 by GTCbio. Infections caused by multidrug-resistant (MDR) gram-negative bacterial pathogens cause great morbidity and mortality worldwide, with a recent study concluding that the spread of resistant pathogens has resulted in higher healthcare and societal costs of $13.5 billion dollars annually in the US. TP-434, a novel fluorocycline, was discovered using a break-through chemistry platform that forms the basis of Tetraphase’s proprietary product engine. TP-434 shows potent activity against a broad range of MDR aerobic and anaerobic gram-negative and gram-positive pathogens both in vitro and in vivo in a variety of murine infection models challenged with MRSA, Streptococcus pneumoniae, S. pyogenes or MDR gram-negative bacteria. With its excellent plasma exposure, volume of distribution, and 40-hour half-life, TP-434 has great potential as a once-daily treatment for serious bacterial infections, especially those caused by MDR gram-negative pathogens.
Dr. Sutcliffe is Senior Vice President, Biology at Tetraphase Pharmaceuticals. She has over 25 years experience in antibiotic research and development. Prior to joining Tetraphase, she was Vice President, Research, of NanoBio Corporation where she led antimicrobial, antiviral and antifungal discovery activities. In addition, she was Chief Research Scientist for 6 years at Rib-X Pharmaceuticals after spending 16 years at Pfizer where she played key roles in early stage antibiotic discovery and development through Phase 2 activities.
Also presenting at the 7th Anti-Infectives Partnering and Deal-Making Summit are prestigious organizations including Novartis, Decision Resources, Tufts University, Allliance for Prudent Uses of Antibiotics, Knobbe Martens Olson & Bear, IDSA, PolyMedix, Baselia, AstraZeneca, Pfizer, Trius Therapeutics, Eli Lilly, Tetraphase and other leaders in the industry.
GTCbio’s Anti-Infectives Partnering & Deal Making-Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry. This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry. For more information, visit www.gtcbio.com.
